Skandinaviska Enskilda Banken AB publ Trims Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Skandinaviska Enskilda Banken AB publ trimmed its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 35.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 84,900 shares of the company’s stock after selling 47,500 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in GoodRx were worth $383,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Point72 Asset Management L.P. purchased a new position in shares of GoodRx in the third quarter worth approximately $11,295,000. Rubric Capital Management LP raised its position in GoodRx by 25.2% in the third quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock worth $32,479,000 after acquiring an additional 943,226 shares during the period. Franklin Resources Inc. purchased a new position in shares of GoodRx during the 3rd quarter worth $5,675,000. Raymond James Financial Inc. bought a new stake in shares of GoodRx during the 4th quarter valued at $2,500,000. Finally, Pier Capital LLC purchased a new stake in shares of GoodRx in the 3rd quarter worth $3,259,000. 63.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GDRX has been the topic of several analyst reports. Citigroup lowered their target price on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research report on Friday, January 10th. Wells Fargo & Company lowered their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Morgan Stanley lowered their price target on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Finally, Mizuho initiated coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

GoodRx Stock Performance

GDRX opened at $4.46 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -148.67, a PEG ratio of 2.46 and a beta of 1.25. The company has a fifty day moving average of $4.72 and a 200 day moving average of $5.48. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.